TruScreen is pleased to announce the appointment of Mr. Reece O'Connell as an independent Non-Executive Director of the Company with effect from today's date.

TruScreen has today released its preliminary unaudited financial results for the financial year ended 31 March 2026.  

TruScreen is pleased to announce the appointment of Albatros Health Care LLC as its distributor in Uzbekistan and the commencement of a pilot clinical study in Tashkent to support market entry, with sales revenue potential NZD1.26m to the end of 2028.

TruScreen is pleased to advise that the Company has received firm commitments from both new and existing investors for an initial placement to institutional and other select investors of approximately 130 million shares at NZ$0.014 / A$0.012 per share to raise approximately NZ$1.82m / A$1.52m before costs.

TruScreen is pleased to announce the launch of an approximately NZ$2.943 million capital raising and issue of Shares today, comprising Placement, Options and Rights Offer.

TruScreen is collaborating with Nigeria’s Lagos State University Teaching Hospital (LASUTH) and Lagos State University College of Medicine (LASUCOM) for a Bill & Melinda Gates Foundation (Gates Foundation) grant application focused on cost-disruptive cervical cancer screening in Nigeria.

Unaudited FY2026 product sales revenue was in line with the guidance provided on 26 February 2026 at approximately NZ$2.4 million, representing an increase of 41% on FY2025. Total unaudited revenue for FY2026 is expected to be approximately NZ$2.8 million, slightly higher than the previous guidance and an increase of around 29% on FY2025.

TruScreen has submitted 3 proposals developed in partnership with leading global and regional health organisations, to deploy TruScreen's portable AI-enabled opto-electronic cervical screening technology across 14 high-burden countries in Africa, AsiaPacific, and Latin America with an addressable market of 1 billion women of screening age.

Mr Christopher Horn has informed the Company of his intention to retire as a non-executive director following the filing of the Company’s Preliminary Final results, expected to be on or around 31 May 2026.

Spark+ Investor Relations Research has published a Research Flash Note on TruScreen Group Limited.

Recognizing the early warning signs of cervical cancer is critical for timely diagnosis and treatment. Although early stage cervical cancer frequently occurs without symptoms, awareness of the signs can help enable early detection and treatment to improve outcomes.

There is a significant global gap in cervical cancer prevention for older women. Reports from public health platforms in China and other parts of Asia reveal that large numbers of older women, especially those in rural or low-resource settings, have never participated in cervical screening programs. This gap places them at high risk for undiagnosed and advanced-stage cervical cancer, with limited treatment options and worse outcomes.

This year’s World Cervical Cancer Elimination Day theme “Act Now: Eliminate Cervical Cancer” calls for bold, united action to build on existing progress and accelerate impact toward the World Health Organization’s 90-70-90 targets by 2030. Read how TruScreen’s innovative, real-time, AI-enabled technology makes cervical screening more accessible, accurate, and sustainable - to support increased screening rates globally.

TruScreen is delighted to be presenting at Aussie Equities Day 2025 hosted by Spark Plus on Friday 3 Oct, during Singapore's F1 GP Week.

Marty Dillon, TruScreen CEO, is presenting the company’s innovative AI enabled cervical cancer screening technology at the Singapore Healthcare Day Forum.

TruScreen had presented at a World Health Organisation (WHO) global meeting to further the use of AI technologies for screening of cervical cancer.

Interim CEO Juliet Hull joins MarketLit's host Lel Smits to discuss TruScreen advantages, advancements and global outlook.